3 March 2015

Director’s Dealing

VERONA PHARMA PLC - Director’s Dealing

PR Newswire

                              Verona Pharma plc

                      ("Verona Pharma" or the "Company")

                              Director's Dealing

3 March 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received
notification that on 3 March 2015 Dr. David Ebsworth, Non-Executive Chairman of
the Company, purchased 450,000 ordinary shares of 0.1p each in the Company
("Ordinary Shares") at an average price of 2.432 pence per share.

Following the acquisition, Dr. Ebsworth will have an interest in the Company of
3,279,774 Ordinary Shares, representing 0.32% of the Company's issued ordinary
share capital.

The Company also received notification today that on 3 March 2015 Biresh Roy,
Chief Financial Officer of the Company, purchased 250,000 ordinary shares of
0.1p each in the Company ("Ordinary Shares") at an average price of 2.432 pence
per share.

Following the acquisition, Biresh Roy will have an interest in the Company of
750,000 Ordinary Shares, representing 0.07% of the Company's issued ordinary
share capital.

                                    -Ends-

For further information please contact:

Verona Pharma plc                       Tel: +44 (0) 20 3283 4200
Jan-Anders Karlsson, CEO

N+1 Singer                              Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer

FTI Consulting                          Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway


Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as COPD, asthma
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class
drug currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential to the
improvement of patients with COPD and asthma. Verona Pharma is also building a
broader franchise around RPL554 to maximise its value, both to patients and to
investors. This includes the very significant markets for COPD and asthma
maintenance therapy. The Company is also exploring the potential of the drug in
different diseases, such as cystic fibrosis, where it is in pre-clinical
testing.

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us